Suppr超能文献

与片剂相比,单次服用25毫克酮洛芬溶液后的药代动力学及相对生物利用度。

Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets.

作者信息

Stiegler S, Birkel M, Jost V, Lange R, Lücker P W, Wetzelsberger N

机构信息

Institut für klinische Pharmakologie Bobenheim, Prof. Dr. Lücker GmbH, Grünstadt, Germany.

出版信息

Methods Find Exp Clin Pharmacol. 1995 Mar;17(2):129-34.

PMID:7674700
Abstract

The relative bioavailability of ketoprofen from a liquid formulation as compared to a tablet formulation as reference after single oral dose administration was investigated in 16 healthy male subjects. The subjects received in a randomized, crossover design during one study period of 5 days 2.5 mg of ketoprofen as tablet or liquid formulation administered as single dose with a washout interval of 48 h. The plasma concentrations of S(+)- and R(-)-ketoprofen were determined before and up to 24 h post-administration. S(+)- and R(-)-ketoprofen in the collected plasma samples was determined using an internally standardized validated HPLC method. Regarding the geometric mean concentration-time courses there were no relevant differences between the two ketoprofen enantiomers for both formulations. Remarkable differences in the shape of concentration-time courses between the two formulations were found with higher Cmax (by about 70%) and earlier tmax (by 15 min) values for the ketoprofen solution. The treatments were widely equivalent with regard to AUC. The quotients of geometric means as well as 90% confidence intervals for AUC of R(-)-ketoprofen were 95.72% (92.55-99.00%) and for S(+)-ketoprofen 94.23% (89.91-98.76%). The administration of the ketoprofen solution resulted earlier in higher concentrations (by about 70%) for both enantiomers, whereas the extent of absorption expressed by AUC was nearly the same (about 95%) as compared to the equimolar tablet formulation. The differences between the two formulations for Cmax,norm and tmax were statistically significant.

摘要

在16名健康男性受试者中,研究了单次口服给药后,酮洛芬液体制剂相对于作为参比的片剂制剂的相对生物利用度。在为期5天的一个研究周期内,受试者采用随机交叉设计,接受2.5mg酮洛芬片剂或液体制剂的单剂量给药,洗脱期为48小时。在给药前及给药后24小时内测定S(+)-和R(-)-酮洛芬的血浆浓度。采用内部标准化的经过验证的高效液相色谱法测定采集的血浆样品中的S(+)-和R(-)-酮洛芬。关于几何平均浓度-时间曲线,两种制剂的两种酮洛芬对映体之间没有显著差异。两种制剂的浓度-时间曲线形状存在显著差异,酮洛芬溶液的Cmax较高(约70%),tmax较早(提前15分钟)。两种治疗方法在AUC方面广泛等效。R(-)-酮洛芬AUC的几何平均商以及90%置信区间为95.72%(92.55-99.00%),S(+)-酮洛芬为94.23%(89.91-98.76%)。酮洛芬溶液给药后,两种对映体的浓度升高更早(约70%),而与等摩尔片剂制剂相比,AUC表示的吸收程度几乎相同(约95%)。两种制剂在Cmax,norm和tmax方面的差异具有统计学意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验